Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

– ARCALYST^® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –
– ARCALYST 2025 net product revenue expected to be $560 - $580 million –
– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –
– Abiprubart development in Sjögren’s Disease to be discontinued –
– Current operating plan expected to remain cash flow positive on an annual basis –
– Conference call and webcast scheduled for 8:30 am ET today –